Unknown

Dataset Information

0

Topical Osmoprotectant for the Management of Postrefractive Surgery-Induced Dry Eye Symptoms: A Randomised Controlled Double-Blind Trial.


ABSTRACT: Background:Dry eye disease (DED) is one of the most common complications following refractive surgery. Purpose:Evaluate the efficacy of an osmoprotective eye drop (Optive®) for the management of induced DED in refractive surgery patients. Design:Double-masked randomised controlled trial. Methods:Twenty-two refractive surgery patients oriented to apply FreshTears (FT; n = 13) or Optive (Op; n = 9), topically, QID, for 3 months. Eye exams were performed before surgery (T0) and 1-month (T1) and 3-month (T3) follow-up and consisted of tear film osmolarity, Schirmer 1 test, tear film breakup time (TBUT), fluorescein staining, and ocular surface disease index (OSDI) and patient symptoms questionnaires. Main Outcome Measures:Pain and osmolarity. Results:Pain increased significantly for FT at T3 (p < 0.05). A reduction in osmolarity was observed at T1 and T3 for Op group (p < 0.01) and at T3 for FT group (p < 0.05). TBUT showed a decrease between T0 and T1 for FT (p < 0.05). Schirmer 1 values increased significantly for Op in T1. Conclusions:Op was superior to FT in regard to pain, osmolarity, TBUT, and Schirmer 1. Osmoprotectant solutes, such as L-carnitine, could attenuate inflammation and secondary DED. Osmoprotective lubricants can be effectively applied for the prevention of refractive surgery-related dry eye symptoms and signs.

SUBMITTER: Hazarbassanov RM 

PROVIDER: S-EPMC5838485 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Topical Osmoprotectant for the Management of Postrefractive Surgery-Induced Dry Eye Symptoms: A Randomised Controlled Double-Blind Trial.

Hazarbassanov R M RM   Queiroz-Hazarbassanov N G T NGT   Barros J N JN   Gomes J A P JAP  

Journal of ophthalmology 20180220


<h4>Background</h4>Dry eye disease (DED) is one of the most common complications following refractive surgery.<h4>Purpose</h4>Evaluate the efficacy of an osmoprotective eye drop (Optive®) for the management of induced DED in refractive surgery patients.<h4>Design</h4>Double-masked randomised controlled trial.<h4>Methods</h4>Twenty-two refractive surgery patients oriented to apply FreshTears (FT; <i>n</i> = 13) or Optive (Op; <i>n</i> = 9), topically, QID, for 3 months. Eye exams were performed b  ...[more]

Similar Datasets

| S-EPMC5081398 | biostudies-other
| S-EPMC7274382 | biostudies-literature
| S-EPMC5991988 | biostudies-literature
| S-EPMC9950493 | biostudies-literature
| S-EPMC7686056 | biostudies-literature
| S-EPMC6218275 | biostudies-literature
| S-EPMC4749988 | biostudies-other
| S-EPMC10252992 | biostudies-literature
| S-EPMC7502384 | biostudies-literature
| S-EPMC8035101 | biostudies-literature